Lexicon Pharmaceuticals Welcomes New CEO and COO
Company Announcements

Lexicon Pharmaceuticals Welcomes New CEO and COO

An announcement from Lexicon Pharmaceuticals (LXRX) is now available.

Michael Exton, Ph.D., with a robust background in pharmaceutical leadership roles, has been appointed as the CEO and board member of a company, effective July 8, 2024. His experience at Novartis and other firms, along with his dual Ph.D.s, positions him as a qualified leader. Dr. Exton’s compensation includes a $636,000 base salary, up to 70% bonus, and stock options, with incentives aligned with corporate goals. Additionally, Jeffrey L. Wade has been promoted to president and COO, receiving a salary bump and stock options, further strengthening the company’s executive team.

For a thorough assessment of LXRX stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyLexicon reports Q3 EPS (18c), consensus (16c)
TheFlyLexicon Pharmaceuticals options imply 14.8% move in share price post-earnings
TheFlyLexicon announces JASN publishes sotagliflozin data
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App